ArticleCureus2026
Real-World Outcomes of Autologous Osteoblast Implantation in Patients With Osteonecrosis of the Femoral Head: A Retrospective, Multicenter, Single-Arm Cohort Study in India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Background Recent advancements in orthobiologics suggest that osteoblast cell therapy combined with core decompression is an emerging approach for the treatment of osteonecrosis of the femoral head (ONFH). This study aimed to assess clinical outcomes in patients with ONFH who underwent osteoblast cell therapy with core decompression. Methods This retrospective, multicenter, single-arm cohort study included patients who underwent osteoblast cell therapy for the treatment of stages I, II, and IIIA ONFH between April 2017 and April 2022, with a follow-up of two to seven years. The primary outcomes included improvements in pain and functional capacity, measured using the Visual Analogue Scale (VAS) score and Harris Hip Score (HHS). The secondary outcome was treatment failure, defined as patients undergoing surgical treatment, including but not limited to total hip arthroplasty (THA), as assessed by the surgeon. Results The study included 319 patients (mean age: 34.4 ± 9.2 years; male: n = 272, 85.3%). Of these, 183 (57.4%) had bilateral ONFH. Of 502 treated hips, most had stage II (n = 226; 45.0%) or stage IIIA (n = 215; 42.8%) ONFH. The mean follow-up was 3.5 years (42.0 ± 5.2 months). The mean change in VAS score (3.78; 95% CI: 3.57-3.99) and HHS (47.01; 95% CI: 45.13-48.89) at follow-up was significant and exceeded the presupposed minimal clinically important difference (MCID). At follow-up, 31 patients (44 hips) required THA; no patient required any other surgical treatment. The patient-wise and hip-wise failure rates were 9.7% and 8.8%, respectively, with a median THA-free survival of 78 months. Conclusions Core decompression with adjuvant osteoblast cell therapy was associated with reduced pain and improved functional capacity in patients with stage I-IIIA ONFH while maintaining femoral head integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.